Imovax® Rabies Vaccine
WISTAR RABIES VIRUS STRAIN PM-1503-3M GROWN IN HUMAN DIPLOID CELL CULTURES
The Imovax® Rabies Vaccine (rabies vaccine) produced by Sanofi Pasteur SA is a sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA.
The virus is harvested from infected human diploid cells, MRC-5 strain, concentrated by ultrafiltration and is inactivated by beta-propiolactone. One dose of reconstituted vaccine contains less than 100 mg albumin, less than 150 μg neomycin sulfate and 20 μg of phenol red indicator. This vaccine must only be used intramuscularly and as a single dose vial.
The vaccine contains no preservative or stabilizer. It should be used immediately after reconstitution, and if not administered promptly, discard contents.
The potency of one dose (1.0 mL) Sanofi Imovax Rabies Vaccine is equal to or greater than 2.5 international units of rabies antigen.
Last reviewed on RxList: 11/10/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Imovax Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.